Abstract
Rab27a, a member of the Rab protein family, can regulate the tumor microenvironment and promote the development of the tumor. Elevated expression of Rab27a is closely connected with many human cancers containing non-small cell lung cancer (NSCLC). But the role of Rab27a in non-small cell lung cancer and its possible mechanism is particularly unclear. In this research, we explored the effect of silencing Rab27a in vitro and in vivo, furnishing evidence that Rab27a could be a potential therapeutic target in NSCLC. Compared with corresponding control cells, silencing Rab27a had decreased ability of cell proliferation, migration and invasion in vitro and slower growth of xenograft tumors in mice. The expressions of apoptosis-associated proteins were induced with a reduction of anti-apoptotic protein in the NSCLC cells down-regulated Rab27a. Furthermore, Rab27a was associated with resistance to conventional chemotherapeutic agents. Our findings suggested that Rab27a might play a critical role in increasing chemosensitivity in NSCLC.
Highlights
Lung cancer is the most common respiratory tract malignancy with the top incidence and mortality
The expression of Rab27a associated in non-small cell lung cancer (NSCLC)
We showed the functional of transfecting the Rab27a expressions in NSCLC cell lines by testing three different sequences of siRNA targeting Rab27a, negative control and without any intervention control siRNA
Summary
Lung cancer is the most common respiratory tract malignancy with the top incidence and mortality. A variety of factors contribute to the occurrence and development of lung cancer. The death rate of lung cancer in developed countries continues to hold the top spot, while in developing countries that is increasing year by year. Stage of lung cancer, and general condition of the patients, the principles of multi-modality treatment including surgery, irradiation, chemotherapy, as well as bio-therapy and gene therapy are extensively discussed [1,2,3]. Cancer metastasis and drug resistance after systematic treatment is still a major problem for patients with lung cancer [4]. Prognosis of patients with lung cancer is ominous, with a 5-year survival rate less than 15% [5].recent researchs of lung cancer are mainly concentrated on the identification of biomarkers in patients and the development of molecularly targeted drugs [6]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call